Inhibiting KDM6A Phosphorylation Suppresses Glycolysis in Oral Squamous Cell Carcinoma

Xin Chen1,2,3, Xin Hu1,2,3, Jun Chen1,2,3

  • 1Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Oral Diseases
|November 18, 2025
PubMed
Abstract

Insights

KDM6A phosphorylation at Ser829, targeted by FBXW7, promotes oral cancer glycolysis and proliferation. This finding reveals KDM6A-pSer829 as a key regulator in oral squamous cell carcinoma (OSCC) metabolism and tumorigenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • KDM6A is crucial in diseases, including cancer, but its role in metabolism is unclear.
  • Understanding KDM6A's post-translational modifications is key to elucidating its function in oral squamous cell carcinoma (OSCC).

Purpose of the Study:

  • To investigate the role of KDM6A post-translational modification in regulating glycolysis in OSCC.
  • To identify specific modifications of KDM6A that impact cancer cell metabolism.

Main Methods:

  • Co-immunoprecipitation and immunoblotting identified KDM6A-pSer829 as an FBXW7 substrate.
  • Generated phospho-dead Kdm6aS829A mice for single-cell RNA sequencing (scRNA-Seq).
  • Utilized 4-nitroquinoline-1-oxide (4NQO) induced OSCC models to assess KDM6A-pS829 effects on proliferation.

Main Results:

  • KDM6A-pSer829 is recognized by FBXW7, leading to ubiquitination and degradation.
  • scRNA-Seq revealed significantly downregulated glycolysis in Kdm6a-S829A mutant cells.
  • Kdm6a-S829A mutation suppressed cell proliferation in a mouse model of OSCC.

Conclusions:

  • KDM6A-pSer829, targeted by FBXW7, promotes glycolysis and proliferation in OSCC.
  • KDM6A-pSer829 is a critical regulator of OSCC metabolism and tumorigenesis.
  • KDM6A-pSer829 represents a potential therapeutic target for OSCC.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K